Patient-guided development
Trials in neuroscience are more burdensome and last longer than in other therapeutic areas, slowing the development of critical new therapies. We describe a pioneering approach to reinvigorate the Alzheimer’s disease clinical research infrastructure for early-stage trials and offer practical advice for engaging and enrolling diverse patient populations.